Pheon Therapeutics, an Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, has announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer. The appointment follows the decision of Bertrand Damour to step down as CEO and coincides with the recent appointment of Jeff Albers as Chairman of the Board.

Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth. Prior to joining Pheon, as an Entrepreneur-in-Residence at Atlas Venture, he co-founded and led Vedere Bio, Inc., serving as Chief Executive Officer from inception right through its sale to Novartis, in a deal valued at $280 million.

Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: “Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics. Our lead program is a first-in-class product that has shown exceptional performance across a range of preclinical efficacy and safety testing. Beyond our lead program, we are leveraging our platform to build a pipeline of high-value ADC products. I am honored and excited to lead this team as we transition into a clinical-stage company and advance our transformative therapies for patients in need.”

Jeff Albers, Chairman of Pheon Therapeutics, commented: “Cyrus’ extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth. He joins our leadership team as we build Pheon’s presence in the US and continue to advance our unique ADCs, a game-changing and rapidly growing modality.“